ACTON, Mass., April 11, 2012 /PRNewswire/ -- Psychemedics Corporation (NASDAQ: PMD) announced that Sarah Ashby has joined the company as Associate General Counsel.
In this important role, Sarah will be responsible for directing and managing all of the company's legal activities. She will report to the company's CEO. Sarah has practiced law with the Boston firms of Campbell Campbell Edwards & Conroy PC, and Wilmer Cutler Pickering Hale & Dorr LLP. Her litigation background includes pharmaceutical and medical device liability, as well as health care fraud investigations, FDA regulation and intellectual property.
Raymond C. Kubacki, Chairman and CEO of Psychemedics, stated "We are extremely pleased to have Sarah joining our team and heading up this important area in our company. Besides providing our clients with the most vigorous drug test available and outstanding client service, we also directly support our clients on any legal challenge. We not only provide a litigation packet and expert testimony, but also legal assistance for our client's legal team to come up to speed quickly. That's why this is such an important role in our company beyond the normal role of Associate General Counsel."About Psychemedics – Psychemedics (NASDAQ: PMD) is the world's leading drug testing company using hair for the detection of drugs of abuse. Psychemedics has been successfully operating for 25 years and thousands of corporations worldwide currently rely on Psychemedics' proprietary hair analysis technology for their pre-employment and employee drug screening. Psychemedics' clients include over 10% of the Fortune 500, some of the largest police departments in America, six Federal Reserve Banks, and schools. For more information, visit the Psychemedics website at www.psychemedics.com . Cautionary Statement for purposes of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995: From time to time, information provided by Psychemedics may contain forward-looking information that involves risks and uncertainties. In particular, statements contained in this release that are not historical facts (including but not limited to statements concerning growth, earnings, profit margins, earnings per share, revenues, dividends, future business, new accounts, customer base, market share, test volume sales and marketing strategies, technological advantages and intellectual property protection) may be "forward looking" statements. Actual results may differ from those stated in any forward-looking statements. Factors that may cause such differences include but are not limited to risks associated with the expansion of the Company's sales and marketing network, development of markets for new products and services offered, the economic health of principal customers of the Company, government regulation, including but not limited to FDA regulations, competition and general economic conditions and other factors disclosed in the Company's filings with the Securities and Exchange Commission.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV